FDA Updates Q&As on Clinical Trials to Evaluate Potential Heart Rhythm Risks

Drug Industry Daily
A A
The FDA published a set of revisions to an ICH supplement, answering industry questions on the evaluation of certain drugs’ potential to produce abnormal heart rhythms.

To View This Article:

Login

Subscribe To Drug Industry Daily